BONE CARE INTERNATIONAL INC
8-K, 2000-02-22
PHARMACEUTICAL PREPARATIONS
Previous: LANVISION SYSTEMS INC, 8-K, 2000-02-22
Next: NUWAVE TECHNOLOGIES INC, 8-K, 2000-02-22





               SECURITIES AND EXCHANGE COMMISSION

                      Washington, DC 20549

                            FORM 8-K

                         Current Report

             Pursuant to Section 13 or 15(d) of the
                Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 14, 2000
                                                  -----------------
                   BONE CARE INTERNATIONAL, INC.
                   -----------------------------
    (Exact Name of Registrant as Specified in Charter)

                          Wisconsin
                          ---------
          State or Other Jurisdiction of Incorporation
        0-27854                            39-1527471
        -------                            ----------
(Commission File Number)      (I.R.S. Employer Identification No.)

 One Science Court, Madison, Wisconsin                  53711
- --------------------------------------                  -----
   (Address of Principal Executive Offices)          (Zip Code)


Registrant's Telephone Number, Including Area Code:  (608) 236-2500

- ------------------------------------------------------------
(Former Name or Former Address, if Changed Since
 Last Report)
Item 4.  Change in Registrant's Certifying Accountant

     (b)  New Independent Accountant

          (i)  On February 14, 2000, Bone Care International, Inc. engaged
Arthur Andersen LLP ("Arthur Andersen") as its independent accountants.
The decision to engage Arthur Andersen LLP was made on the recommendation
of the Audit Committee of the Board of Directors.

          (ii) During the two most recent fiscal years and interim periods
subsequent to June 30, 1999 and prior to engaging Arthur Andersen, neither
the Registrant nor anyone on its behalf consulted Arthur Andersen regarding
the application of accounting principles to a specified transaction, either
completed or proposed, or the type of audit opinion that might be rendered
on the Registrant's financial statements or, except as described in (iii)
below, any matter that was either the subject of a disagreement (as defined
in Regulation S-K item 304(a)(i)(iv)) or a reportable event (as defined in
Regulation S-K item 304(a)(i)(v)).

          (iii)     During the period from July 1, 1999 through January 27,
2000, the Registrant had discussions with KPMG related to the appropriate
reserve for returns of Hectorol, Registrant's first commercially available
product.  At the time of dismissal of KPMG, the Registrant had not resolved
with KPMG the appropriate reserve amount for the Registrant's financial
statements.  Prior to January 27, 2000 when Registrant dismissed KPMG LLP
("KPMG") as its independent accountants, Registrant did not consult Arthur
Andersen LLP regarding any matter which was the subject of a disagreement
between Registrant and KPMG .   On February 11, 2000, Registrant began to
consult Arthur Andersen concerning the appropriate reserve amount for
returns of Hectorol, and Arthur Andersen assisted Registrant in drafting
a response filed February 15, 2000 with the Securities Exchange Commission
concerning Registrant's reserve policy.  Arthur Andersen has orally expressed
its concurrence with Registrant's reserve policy.  Registrant did not consult
KPMG concerning these matters following the dismissal of KPMG.


                         SIGNATURES

              Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.


Date:  February 21, 2000


                              BONE CARE INTERNATIONAL, INC.


                              By:  /s/ Richard B. Mazess, Ph.D.
                                   ----------------------------
                                     Richard B. Mazess, Ph.D.
                                     Chairman and Director




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission